GlassScriptPhysician profile
Alice Chapman
NPI 1386185510
$2,548.53
in general payments reported to CMS, 2019-2025
23 companies · $564 in 2025
The $564 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $672 · 2023: $293 · 2024: $637 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.39 |
| Education | $175.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $658.84 | 2021-2025 | Veozah |
| Mayne Pharma Commercial LLC | $251.39 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $219.60 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $217.41 | 2021-2024 | |
| Abbvie INC. | $148.41 | 2021-2022 | |
| Daiichi Sankyo INC. | $138.61 | 2021-2023 | Injectafer |
| Myovant Sciences INC. | $114.33 | 2021-2022 | |
| Sage Therapeutics, LLC | $99.86 | 2022-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $93.23 | 2021-2025 | Gardasil 9, Gardasil |
| Organon LLC | $84.70 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $65.49 | 2021-2022 | |
| Millicent US INC | $60.88 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Coopersurgical, INC. | $57.57 | 2022-2024 | Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Exeltis, USA INC. | $50.30 | 2021-2024 | Slynd |
| Exact Sciences Corporation | $48.31 | 2024-2025 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $47.86 | 2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Avion Pharmaceuticals | $43.21 | 2021-2022 | |
| Amgen INC. | $38.10 | 2022-2024 | Prolia, Evenity |
| Renovia INC | $36.92 | 2021 | |
| Shield Therapeutics INC | $22.41 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.27 | 2021 | |
| Aspira Women'S Health INC | $18.94 | 2021 | |
| Evofem Biosciences, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.